Comparative Effectiveness of Biomarkers to Target Cancer Treatment

Jeanette K. Birnbaum, Foluso O. Ademuyiwa, Josh J. Carlson, Leslie Mallinger, Mark W. Mason, Ruth Etzioni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Biomarkers used at the time of diagnosis to tailor treatment decisions may diffuse into clinical practice before data become available on whether biomarker testing reduces cancer mortality. In the interim, quantitative estimates of the mortality impact of testing are needed to assess the value of these diagnostic biomarkers. These estimates are typically generated by customized models that are resource intensive to build and apply. Methods. We developed a user-friendly system of models for Cancer Translation of Comparative Effectiveness Research (CANTRANce) to model the mortality impact of cancer interventions. The Diagnostic Biomarker module of this system projects the mortality impact of testing for a diagnostic biomarker, given data on how testing affects treatment recommendations. Costs and quality-of-life outcomes may also be modeled. We applied the Diagnostic Biomarker module to 2 case studies to demonstrate its capabilities. Results. The user interface (http://www.fhcrc.org/cantrance) allows comparative effectiveness researchers to use the Diagnostic Biomarker module of CANTRANce. Our case studies indicate that the model produces estimates on par with those generated by customized models and is a strong tool for quickly generating novel projections. Limitations. The simple structure that makes CANTRANce user-friendly also constrains the complexity with which cancer progression can be modeled. The quality of the results rests on the quality of the input data, which may pertain to small or dissimilar populations or suffer from informative censoring. Conclusions. The Diagnostic Biomarker module of CANTRANce is a novel public resource that can provide timely insights into the expected mortality impact of testing for diagnostic biomarkers. The model projections should be useful for understanding the long-Term potential of emerging diagnostic biomarkers.

Original languageEnglish (US)
Pages (from-to)594-603
Number of pages10
JournalMedical Decision Making
Volume36
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Biomarkers
Comparative Effectiveness Research
Neoplasms
Mortality
Tumor Biomarkers
Quality of Life
Research Personnel
Costs and Cost Analysis
Population

Keywords

  • breast cancer
  • comparative effectiveness
  • decision analysis
  • outcomes research
  • simulation methods

ASJC Scopus subject areas

  • Health Policy

Cite this

Birnbaum, J. K., Ademuyiwa, F. O., Carlson, J. J., Mallinger, L., Mason, M. W., & Etzioni, R. (2015). Comparative Effectiveness of Biomarkers to Target Cancer Treatment. Medical Decision Making, 36(5), 594-603. https://doi.org/10.1177/0272989X15601998

Comparative Effectiveness of Biomarkers to Target Cancer Treatment. / Birnbaum, Jeanette K.; Ademuyiwa, Foluso O.; Carlson, Josh J.; Mallinger, Leslie; Mason, Mark W.; Etzioni, Ruth.

In: Medical Decision Making, Vol. 36, No. 5, 01.01.2015, p. 594-603.

Research output: Contribution to journalArticle

Birnbaum, JK, Ademuyiwa, FO, Carlson, JJ, Mallinger, L, Mason, MW & Etzioni, R 2015, 'Comparative Effectiveness of Biomarkers to Target Cancer Treatment', Medical Decision Making, vol. 36, no. 5, pp. 594-603. https://doi.org/10.1177/0272989X15601998
Birnbaum JK, Ademuyiwa FO, Carlson JJ, Mallinger L, Mason MW, Etzioni R. Comparative Effectiveness of Biomarkers to Target Cancer Treatment. Medical Decision Making. 2015 Jan 1;36(5):594-603. https://doi.org/10.1177/0272989X15601998
Birnbaum, Jeanette K. ; Ademuyiwa, Foluso O. ; Carlson, Josh J. ; Mallinger, Leslie ; Mason, Mark W. ; Etzioni, Ruth. / Comparative Effectiveness of Biomarkers to Target Cancer Treatment. In: Medical Decision Making. 2015 ; Vol. 36, No. 5. pp. 594-603.
@article{4742291e58f14dfa8706af564d5ca634,
title = "Comparative Effectiveness of Biomarkers to Target Cancer Treatment",
abstract = "Background. Biomarkers used at the time of diagnosis to tailor treatment decisions may diffuse into clinical practice before data become available on whether biomarker testing reduces cancer mortality. In the interim, quantitative estimates of the mortality impact of testing are needed to assess the value of these diagnostic biomarkers. These estimates are typically generated by customized models that are resource intensive to build and apply. Methods. We developed a user-friendly system of models for Cancer Translation of Comparative Effectiveness Research (CANTRANce) to model the mortality impact of cancer interventions. The Diagnostic Biomarker module of this system projects the mortality impact of testing for a diagnostic biomarker, given data on how testing affects treatment recommendations. Costs and quality-of-life outcomes may also be modeled. We applied the Diagnostic Biomarker module to 2 case studies to demonstrate its capabilities. Results. The user interface (http://www.fhcrc.org/cantrance) allows comparative effectiveness researchers to use the Diagnostic Biomarker module of CANTRANce. Our case studies indicate that the model produces estimates on par with those generated by customized models and is a strong tool for quickly generating novel projections. Limitations. The simple structure that makes CANTRANce user-friendly also constrains the complexity with which cancer progression can be modeled. The quality of the results rests on the quality of the input data, which may pertain to small or dissimilar populations or suffer from informative censoring. Conclusions. The Diagnostic Biomarker module of CANTRANce is a novel public resource that can provide timely insights into the expected mortality impact of testing for diagnostic biomarkers. The model projections should be useful for understanding the long-Term potential of emerging diagnostic biomarkers.",
keywords = "breast cancer, comparative effectiveness, decision analysis, outcomes research, simulation methods",
author = "Birnbaum, {Jeanette K.} and Ademuyiwa, {Foluso O.} and Carlson, {Josh J.} and Leslie Mallinger and Mason, {Mark W.} and Ruth Etzioni",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/0272989X15601998",
language = "English (US)",
volume = "36",
pages = "594--603",
journal = "Medical decision making : an international journal of the Society for Medical Decision Making",
issn = "0272-989X",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Comparative Effectiveness of Biomarkers to Target Cancer Treatment

AU - Birnbaum, Jeanette K.

AU - Ademuyiwa, Foluso O.

AU - Carlson, Josh J.

AU - Mallinger, Leslie

AU - Mason, Mark W.

AU - Etzioni, Ruth

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background. Biomarkers used at the time of diagnosis to tailor treatment decisions may diffuse into clinical practice before data become available on whether biomarker testing reduces cancer mortality. In the interim, quantitative estimates of the mortality impact of testing are needed to assess the value of these diagnostic biomarkers. These estimates are typically generated by customized models that are resource intensive to build and apply. Methods. We developed a user-friendly system of models for Cancer Translation of Comparative Effectiveness Research (CANTRANce) to model the mortality impact of cancer interventions. The Diagnostic Biomarker module of this system projects the mortality impact of testing for a diagnostic biomarker, given data on how testing affects treatment recommendations. Costs and quality-of-life outcomes may also be modeled. We applied the Diagnostic Biomarker module to 2 case studies to demonstrate its capabilities. Results. The user interface (http://www.fhcrc.org/cantrance) allows comparative effectiveness researchers to use the Diagnostic Biomarker module of CANTRANce. Our case studies indicate that the model produces estimates on par with those generated by customized models and is a strong tool for quickly generating novel projections. Limitations. The simple structure that makes CANTRANce user-friendly also constrains the complexity with which cancer progression can be modeled. The quality of the results rests on the quality of the input data, which may pertain to small or dissimilar populations or suffer from informative censoring. Conclusions. The Diagnostic Biomarker module of CANTRANce is a novel public resource that can provide timely insights into the expected mortality impact of testing for diagnostic biomarkers. The model projections should be useful for understanding the long-Term potential of emerging diagnostic biomarkers.

AB - Background. Biomarkers used at the time of diagnosis to tailor treatment decisions may diffuse into clinical practice before data become available on whether biomarker testing reduces cancer mortality. In the interim, quantitative estimates of the mortality impact of testing are needed to assess the value of these diagnostic biomarkers. These estimates are typically generated by customized models that are resource intensive to build and apply. Methods. We developed a user-friendly system of models for Cancer Translation of Comparative Effectiveness Research (CANTRANce) to model the mortality impact of cancer interventions. The Diagnostic Biomarker module of this system projects the mortality impact of testing for a diagnostic biomarker, given data on how testing affects treatment recommendations. Costs and quality-of-life outcomes may also be modeled. We applied the Diagnostic Biomarker module to 2 case studies to demonstrate its capabilities. Results. The user interface (http://www.fhcrc.org/cantrance) allows comparative effectiveness researchers to use the Diagnostic Biomarker module of CANTRANce. Our case studies indicate that the model produces estimates on par with those generated by customized models and is a strong tool for quickly generating novel projections. Limitations. The simple structure that makes CANTRANce user-friendly also constrains the complexity with which cancer progression can be modeled. The quality of the results rests on the quality of the input data, which may pertain to small or dissimilar populations or suffer from informative censoring. Conclusions. The Diagnostic Biomarker module of CANTRANce is a novel public resource that can provide timely insights into the expected mortality impact of testing for diagnostic biomarkers. The model projections should be useful for understanding the long-Term potential of emerging diagnostic biomarkers.

KW - breast cancer

KW - comparative effectiveness

KW - decision analysis

KW - outcomes research

KW - simulation methods

UR - http://www.scopus.com/inward/record.url?scp=84971215754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971215754&partnerID=8YFLogxK

U2 - 10.1177/0272989X15601998

DO - 10.1177/0272989X15601998

M3 - Article

C2 - 26304062

AN - SCOPUS:84971215754

VL - 36

SP - 594

EP - 603

JO - Medical decision making : an international journal of the Society for Medical Decision Making

JF - Medical decision making : an international journal of the Society for Medical Decision Making

SN - 0272-989X

IS - 5

ER -